← Back to Search

Unknown

AGN-241622 for Presbyopia

Phase 1 & 2
Waitlist Available
Research Sponsored by Allergan
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 14 days

Summary

This trial is testing AGN-241622 eye drops to see if they are safe and effective. The study will check if the drops help with eye conditions without causing side effects.

Eligible Conditions
  • Presbyopia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~14 days
This trial's timeline: 3 weeks for screening, Varies for treatment, and 14 days for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Stage 1: Number of Participants Experiencing a Treatment Emergent Adverse Event After Single Administration of AGN-241622
Stage 2a: Number of Patients Experiencing a Treatment Emergent Adverse Event After Repeat Administration of AGN-241622
Secondary study objectives
Stage 1 Plasma Pharmacokinetics: Apparent Total Clearance of AGN-241622 From Plasma (CL/F)
Stage 1 Plasma Pharmacokinetics: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC0-inf) of AGN-241622
Stage 1 Plasma Pharmacokinetics: Area Under the Concentration-time Curve From Time 0 to Time t (AUC0-t) of AGN-241622
+28 more

Trial Design

7Treatment groups
Experimental Treatment
Placebo Group
Group I: Cohort 6: AGN-241622 Dose 3 (High Dose)Experimental Treatment1 Intervention
Administered as single drop in each eye
Group II: Cohort 5: AGN-241622 Dose 2 (Medium Dose)Experimental Treatment1 Intervention
Administered as single drop in each eye
Group III: Cohort 4: AGN-241622 Dose 1 (Low Dose)Experimental Treatment1 Intervention
Administered as a single drop in each eye
Group IV: Cohort 3: AGN-241622 Dose 3 (High Dose)Experimental Treatment1 Intervention
Administered as single drop in one eye
Group V: Cohort 2: AGN-241622 Dose 2 (Medium Dose)Experimental Treatment1 Intervention
Administered as single drop in one eye
Group VI: Cohort 1: AGN-241622 Dose 1 (Low Dose)Experimental Treatment1 Intervention
Administered as single drop in one eye
Group VII: Placebo DosePlacebo Group1 Intervention
Administered as single drop in one or both eyes

Find a Location

Who is running the clinical trial?

AllerganLead Sponsor
781 Previous Clinical Trials
276,574 Total Patients Enrolled
8 Trials studying Presbyopia
1,402 Patients Enrolled for Presbyopia
AbbVieLead Sponsor
1,023 Previous Clinical Trials
520,209 Total Patients Enrolled
2 Trials studying Presbyopia
43 Patients Enrolled for Presbyopia
Wayne Chen, PharmDStudy DirectorAllergan
~15 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top